23andMe Investor Presentation Deck

● Primary Human T Cells CD200R1 '610 Differentiated Combo Potential: Anti-CD200R1 with Anti-PD-1 Potentially Enhances Immune Activation CD200 T Cell Activation TCR aCD3 CHO cells PD1 PDL1 +23ME-00610 + anti-PD-1 23ME-00610 CD200 2 ug/mL per antibody. Representative data from one of four donors tested. Statistics: Ordinary one- way ANOVA with Tukey's multiple comparisons test, **p<0.01, ****p<0.0001 T Cell Activation TCR IFN-Y. aCD3 CHO cells anti-PD-1 PDL1 IFNY (pg/mL) 3600- 3000- 2400- 1800- 1200- 600- 0 IFNY Secretion Isotype **** **** anti-PD-1 23ME-00610 Preliminary data from ex-vivo combination of anti-PD-1 and anti-CD200R1 blockade increased IFNY (interferon-gamma) secretion from primary human T-cells Ob Copyright © 2024 23and Me, Inc. 7 Combo *23andMe internal data 23andMe 29

View entire presentation